Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6132177 | 0.95 | PTPN11 (0.50) | PTPN11CA1CA2TDP1CA12 | |
| SCHEMBL6135654 | 0.92 | MAPT (0.50) | PTPN11CA1CA2TDP1CA12 | |
| SCHEMBL404124 | 0.88 | PTPN11 (0.50) | PTPN11CA1CA2TDP1CA12 | |
| SCHEMBL69268 | 0.85 | PTPN11 (0.69) | PTPN11CA1CA2TDP1CA12 | |
| SCHEMBL19554149 | 0.84 | PTPN11 (0.48) | PTPN11CA1CA2CA12CA7 | |
| SCHEMBL19712252 | 0.82 | KDM4E (0.46) | PTPN11CA1CA2TDP1CA12 | |
| SCHEMBL15400163 | 0.82 | KDM4E (0.46) | CA1CA2TDP1CA12CA7 | |
| SCHEMBL10894607 | 0.82 | USP2 (0.45) | PTPN11CA1CA2CA12CA7 | |
| SCHEMBL9805558 | 0.81 | GABRA1 (0.51) | PTPN11CA1CA2CA12CA9 | |
| SCHEMBL1348968 | 0.81 | CA12 (0.54) | CA1CA2TDP1CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282801-A1 | TRITYL-BASED ALCOHOL PROTECTING GROUP | SYNCREST INC. (JP) | 2025-09-11 | — | — | US | disclosed |
| US-12331057-B2 | Modulators of alpha-1 antitrypsin | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-17 | — | — | US | disclosed |
| US-20240336614-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2024-10-10 | — | — | US | disclosed |
| WO-2024043198-A1 | TRITYL-BASED ALCOHOL PROTECTING GROUP | シンクレスト株式会社 | 2024-02-29 | — | — | WO | disclosed |
| WO-2024043198-A1 | TRITYL-BASED ALCOHOL PROTECTING GROUP | シンクレスト株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-11884672-B2 | Modulators of alpha-1 antitrypsin | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-01-30 | — | — | US | disclosed |
| CN-112074507-B | Compounds as Antibiotics | 山东亨利医药科技有限责任公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20230052586-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-02-16 | — | — | US | disclosed |
| EP-3898588-B1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-01-11 | — | — | EP | disclosed |
| US-11498909-B2 | Compound acting as antibiotics | KBP BIOSCIENCES CO., LTD. (CN) | 2022-11-15 | — | — | US | disclosed |
| WO-2000039087-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| US-6046220-A | ADMINISTERING TO THE PATIENT A PROPYNYL OR DIENYL BIAROMATIC COMPOUND TO TREAT A SKIN DISORDER, INFLAMMATORY CONDITIONS, VISION DEFECTS, ALOPECIA, CARDIOVASCULAR DISORDER, CANCER OR PRECANCER AND INSULIN DEPENDANT DIABETES | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-04-04 | — | — | US | disclosed |
| US-5786379-A | Adamantyl-substituted biaromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-07-28 | — | — | US | disclosed |
| US-5747530-A | Aromatic dibenzofuran compounds and pharmaceutical/cosmetic compositions comprised thereof | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-05-05 | — | — | US | disclosed |
| US-5716624-A | USEFUL FOR TREATING DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR, OPTHALMOLOGICAL DISORDERS, AS WELL AS MAMMALIAN SKIN AND HAIR CONDITIONS/DISORDERS | C.I.R.D. GALDERMA (FR) | 1998-02-10 | — | — | US | disclosed |
| US-5626792-A | DIPHENYLACETYLENE ESTERS, THIOESTERS OR DITHIOESTERS | DISPLAYTECH, INC. (US) | 1997-05-06 | — | — | US | disclosed |
| US-4638083-A | ESTERIFICATION OF HYDROXY COMPOUND WITH ETHYNYL BENZOYL CHLORIDE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS & SPACE ADMINISTRATION (US) | 1987-01-20 | — | — | US | disclosed |
| US-4567240-A | Ethynyl terminated ester oligomers and polymers therefrom | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION (US) | 1986-01-28 | — | — | US | disclosed |
| US-4465833-A | ALKYNYLATION HALOGENATED BENZENE COMPOUND IN PRESENCE OF METAL CATALYST | HUGHES AIRCRAFT COMPANY (US) | 1984-08-14 | — | — | US | disclosed |
| EP-0050428-A1 | Ethynylated aromatic compounds and process for making same | Hughes Aircraft Company (US) | 1982-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336614-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINC1, SERPINA3 | PTPN11 3166/4885CA1 2768/4885CA2 4185/4885 |
| US-11884672-B2 | Modulators of alpha-1 antitrypsin | SERPINA2, SERPINC1, SERPINA3 | PTPN11 3166/4885CA1 2768/4885CA2 4185/4885 |
| US-11498909-B2 | Compound acting as antibiotics | PEPD, NRDC, DPP4 | PTPN11 2102/4885CA1 4040/4885CA2 2864/4885 |
| US-20250282801-A1 | TRITYL-BASED ALCOHOL PROTECTING GROUP | POT1, ADH1A, ADH5 | PTPN11 4164/4885CA1 2341/4885CA2 3812/4885 |
| US-20230052586-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | BRCA1, MYC, PCNA | PTPN11 1542/4885CA1 4883/4885CA2 4672/4885 |
| US-12331057-B2 | Modulators of alpha-1 antitrypsin | SERPINA2, SERPINC1, SERPINA3 | PTPN11 3166/4885CA1 2768/4885CA2 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.